Please assess the completion status of the following clinical trial:

Trial Title: Pediatric REPlAcement of the PulmonaRy ValvE in Tetralogy of Fallot -

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females with repaired Tetralogy of Fallot (TOF), currently between 13 and 21 years of age.~2. On clinical Cardiac Magnetic Resonance (CMR) : Right Ventricular End-Diastolic Volume Index (RVEDVi) between 140 and 180 cc/m2 inclusive with Right Ventricular End-Diastolic Function (RVEF) \> 40% and Left Right Ventricular End-Diastolic (LVEF ) \> 50%, RV outflow tract peak velocity \< 3 meters/second (if not available this will be skipped); there will be no indexed Right Ventricular end-systolic volume (RVESVi) criteria; by defining RVEDVi and RVEF, Investigators will be inherently defining RVESVi~3. On clinical echocardiogram: RV outflow tract peak velocity \< 3 meters/second (if not available this will be skipped), at least mild pulmonary insufficiency and tricuspid regurgitation with an RV pressure estimate \< 1/2 systemic pressure.~4. On Exercise Stress Test (EST), aerobic capacity \> 60% of predicted.~5. No Q-wave, R-wave, S-wave (QRS) duration criteria on ECG.~Exclusion Criteria:~1. Any condition judged by the patient's physician that would cause this trial to be detrimental to the patient.~2. Specific forms of TOF excluded are those with endocardial cushion defects, TOF with absent pulmonary valve and TOF with multiple aorto-pulmonary collaterals requiring unifocalization.~3. Unilateral branch pulmonary artery stenosis (one lung receives \< 25% of total flow)~4. Contraindication to non-sedated exercise CMR (e.g. pacemaker/implanted cardioverter defibrillator); need for sedation~5. If data available, moderate or greater tricuspid regurgitation on echocardiogram or CMR or Qp/Qs \> 1.5~6. Significant strokes/hemiplegia or inability to exercise~7. Genetic syndrome/developmental delay which would make QOL and EST date uninterpretable~8. Pregnancy~9. Previous pulmonary valve replacement (PVR)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- PVR Arm (Type: OTHER): PVR arm will undergo PVR via catheter or surgery
- No PVR (Type: NO_INTERVENTION): No PVR group will continue with medical management

Based on this trial design, predict the completion outcome and termination type (if applicable).